AR058955A1 - Inmunglobulinas que se unen a interleuquina 13 - Google Patents
Inmunglobulinas que se unen a interleuquina 13Info
- Publication number
- AR058955A1 AR058955A1 ARP070100082A ARP070100082A AR058955A1 AR 058955 A1 AR058955 A1 AR 058955A1 AR P070100082 A ARP070100082 A AR P070100082A AR P070100082 A ARP070100082 A AR P070100082A AR 058955 A1 AR058955 A1 AR 058955A1
- Authority
- AR
- Argentina
- Prior art keywords
- antibodies
- hll
- diseases
- seq
- amino acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
- A61P33/12—Schistosomicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Plant Pathology (AREA)
- Otolaryngology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Anticuerpos que se unen específicamente a interleucina 13 humana (hlL-13). Los anticuerpos pueden utilizarse para el tratamiento de una variedad de enfermedades o trastornos sensibles a la modulacion de la interaccion entre hlL-13 y el receptor de IL-13 humana. Dichas enfermedades incluyen asma grave, dermatitis atopica, EPOC y diversas enfermedades fibroticas, composiciones farmacéuticas que comprenden dichos anticuerpos y procedimientos de fabricacion. Reivindicacion 1: Un anticuerpo o fragmento de union a antígeno del mismo que se une específicamente a hlL-13 y comprende CDRH3 como se define en la SEC N° ID 3 o variantes de la misma en las que uno o dos restos de aminoácidos en dicha CDRH3 difieren de los restos de aminoácidos en la correspondiente posicion en la SEC N° ID 3.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0600488.1A GB0600488D0 (en) | 2006-01-11 | 2006-01-11 | Immunoglobulins |
Publications (1)
Publication Number | Publication Date |
---|---|
AR058955A1 true AR058955A1 (es) | 2008-03-05 |
Family
ID=35997844
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP070100082A AR058955A1 (es) | 2006-01-11 | 2007-01-09 | Inmunglobulinas que se unen a interleuquina 13 |
Country Status (18)
Country | Link |
---|---|
EP (1) | EP1976881A2 (es) |
JP (1) | JP2009523154A (es) |
KR (1) | KR20080113201A (es) |
CN (1) | CN101370829A (es) |
AR (1) | AR058955A1 (es) |
AU (1) | AU2007204372A1 (es) |
BR (1) | BRPI0706481A2 (es) |
CA (1) | CA2635972A1 (es) |
CR (1) | CR10161A (es) |
EA (1) | EA200801520A1 (es) |
GB (1) | GB0600488D0 (es) |
IL (1) | IL192207A0 (es) |
MA (1) | MA30156B1 (es) |
NO (1) | NO20082767L (es) |
PE (1) | PE20081185A1 (es) |
TW (1) | TW200736274A (es) |
WO (1) | WO2007080174A2 (es) |
ZA (1) | ZA200805526B (es) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2532678A1 (en) | 2005-10-21 | 2012-12-12 | Novartis AG | Human antibodies against il13 and therapeutic uses |
NZ572565A (en) | 2006-05-25 | 2011-04-29 | Glaxo Group Ltd | Modified humanised anti-interleukin-18 antibodies |
EP2050764A1 (en) * | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
SG171733A1 (en) * | 2008-11-26 | 2011-07-28 | Glaxo Group Ltd | Ligands that bind il-13 |
NZ594514A (en) | 2009-03-05 | 2013-06-28 | Abbott Lab | Interleukin-17 BINDING PROTEINS |
GB0904214D0 (en) | 2009-03-11 | 2009-04-22 | Ucb Pharma Sa | Biological products |
AU2010251955A1 (en) * | 2009-05-28 | 2011-12-22 | Glaxo Group Limited | IL-13 binding protein |
MX2012004711A (es) | 2009-10-20 | 2012-05-23 | Abbott Lab | Aislamiento y purificacion de los anticuerpos anti-il-13 al usar cromatografia de afinidad con proteina a. |
CN103328506A (zh) * | 2010-10-15 | 2013-09-25 | 米迪缪尼有限公司 | 用于改善肺功能的疗法 |
BR112013013460A8 (pt) | 2010-12-16 | 2019-02-12 | Genentech Inc | métodos de identificação de um paciente com asma, método de monitoramento de um paciente com asma, uso de um kit de detecção de periostina total, kit de medição da periostina total, uso de um anticorpo anti-il-13, uso de uma quantidade terapeuticamente eficaz de lebrikizumab, uso de um inibidor da via de th2, método de avaliação de eventos adversos, anticorpo anti-periostina e teste de periostina total |
PL3235508T3 (pl) | 2011-03-16 | 2021-07-12 | Sanofi | Kompozycje zawierające białko podobne do przeciwciała z podwójnym regionem v |
WO2015061441A1 (en) | 2013-10-23 | 2015-04-30 | Genentech, Inc. | Methods of diagnosing and treating eosinophilic disorders |
KR20160124165A (ko) | 2014-02-21 | 2016-10-26 | 제넨테크, 인크. | 항-il-13/il-17 이중특이적 항체 및 그의 용도 |
CA2943326A1 (en) | 2014-04-11 | 2015-10-15 | Novartis Ag | Methods of selectively treating asthma using il-13 antagonists |
WO2016149276A1 (en) | 2015-03-16 | 2016-09-22 | Genentech, Inc. | Methods of detecting and quantifying il-13 and uses in diagnosing and treating th2-associated diseases |
EP3433615A1 (en) | 2016-03-21 | 2019-01-30 | Institut National de la Sante et de la Recherche Medicale (INSERM) | Methods for diagnosis and treatment of solar lentigo |
US20190359722A1 (en) * | 2017-01-23 | 2019-11-28 | Toyo University | Anti-epha2 antibody and immunological detection of epha2 using same |
CN109776677B (zh) * | 2017-11-15 | 2023-11-03 | 尚华科创投资管理(江苏)有限公司 | 一种人源化抗il-13抗体及其制备方法和应用 |
CN107909501B (zh) * | 2017-12-05 | 2020-12-01 | 创新先进技术有限公司 | 气味与行为的关联方法、气味社交方法及装置 |
CA3088557C (en) | 2018-02-09 | 2024-02-27 | Genentech, Inc. | Therapeutic and diagnostic methods for mast cell-mediated inflammatory diseases |
WO2020092015A1 (en) | 2018-11-02 | 2020-05-07 | University Of Rochester | Therapeutic mitigation of epithelial infection |
CN114008079A (zh) * | 2019-03-20 | 2022-02-01 | 贾夫林肿瘤学公司 | 抗adam12抗体和嵌合抗原受体以及包含其的组合物和方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003260748A1 (en) * | 2002-08-30 | 2004-03-19 | Glaxo Group Limited | Il-14 vaccine for the treatment of asthma and atopic disorders |
WO2004096849A2 (en) * | 2003-04-25 | 2004-11-11 | University Of Manitoba | Peptide-based cytokine/chemokine vaccines against allergy |
SG10201900535UA (en) * | 2003-12-23 | 2019-02-27 | Genentech Inc | Novel anti-il 13 antibodies and uses thereof |
US7501121B2 (en) * | 2004-06-17 | 2009-03-10 | Wyeth | IL-13 binding agents |
TWI307630B (en) * | 2004-07-01 | 2009-03-21 | Glaxo Group Ltd | Immunoglobulins |
-
2006
- 2006-01-11 GB GBGB0600488.1A patent/GB0600488D0/en not_active Ceased
-
2007
- 2007-01-09 TW TW096100833A patent/TW200736274A/zh unknown
- 2007-01-09 AR ARP070100082A patent/AR058955A1/es unknown
- 2007-01-09 PE PE2007000018A patent/PE20081185A1/es not_active Application Discontinuation
- 2007-01-10 WO PCT/EP2007/050219 patent/WO2007080174A2/en active Application Filing
- 2007-01-10 EA EA200801520A patent/EA200801520A1/ru unknown
- 2007-01-10 KR KR1020087019555A patent/KR20080113201A/ko not_active Application Discontinuation
- 2007-01-10 CN CNA2007800022973A patent/CN101370829A/zh active Pending
- 2007-01-10 JP JP2008549873A patent/JP2009523154A/ja active Pending
- 2007-01-10 AU AU2007204372A patent/AU2007204372A1/en not_active Abandoned
- 2007-01-10 CA CA002635972A patent/CA2635972A1/en not_active Abandoned
- 2007-01-10 EP EP07703766A patent/EP1976881A2/en not_active Withdrawn
- 2007-01-10 BR BRPI0706481-0A patent/BRPI0706481A2/pt not_active IP Right Cessation
-
2008
- 2008-06-16 IL IL192207A patent/IL192207A0/en unknown
- 2008-06-16 NO NO20082767A patent/NO20082767L/no not_active Application Discontinuation
- 2008-06-24 ZA ZA200805526A patent/ZA200805526B/xx unknown
- 2008-07-11 MA MA31108A patent/MA30156B1/fr unknown
- 2008-07-17 CR CR10161A patent/CR10161A/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
MA30156B1 (fr) | 2009-01-02 |
CN101370829A (zh) | 2009-02-18 |
KR20080113201A (ko) | 2008-12-29 |
NO20082767L (no) | 2008-10-06 |
TW200736274A (en) | 2007-10-01 |
WO2007080174A3 (en) | 2007-12-06 |
EP1976881A2 (en) | 2008-10-08 |
EA200801520A1 (ru) | 2009-02-27 |
JP2009523154A (ja) | 2009-06-18 |
WO2007080174A2 (en) | 2007-07-19 |
GB0600488D0 (en) | 2006-02-22 |
ZA200805526B (en) | 2009-10-28 |
IL192207A0 (en) | 2008-12-29 |
BRPI0706481A2 (pt) | 2011-03-29 |
CA2635972A1 (en) | 2007-07-19 |
AU2007204372A1 (en) | 2007-07-19 |
PE20081185A1 (es) | 2008-10-07 |
CR10161A (es) | 2008-11-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR058955A1 (es) | Inmunglobulinas que se unen a interleuquina 13 | |
CY1120414T1 (el) | Αντισωματα που συνδεονται me οχ40 και οι χρησεις τους | |
AU2018256487A1 (en) | Antibodies that bind to TL1A and their uses | |
AR049565A1 (es) | Anticuerpos de union a interleuquina 13 humana | |
EA200801842A1 (ru) | Антитела против бета-амилоидного пептида | |
CO6430469A2 (es) | Anticuerpos humanizados que se unen a cd19 y sus usos | |
NZ706377A (en) | Il-6 antagonists and uses thereof | |
UA116772C2 (uk) | Виділене моноклональне антитіло або його імунологічно-активний фрагмент, що зв'язується з cd47 | |
AR059604A1 (es) | Anticuerpos contra il- 22 humana y usos para los mismos | |
CA2813849C (en) | Secukinumab for use in the treatment of ankylosing spondylitis | |
AR072897A1 (es) | Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c5 | |
BR112015014751A2 (pt) | anticorpos anti-tau humanos | |
AR070346A1 (es) | Anticuerpo especifico del receptor de linfopoyetina estromal timica (tslpr) y usos en trastornos inflamatorios e inflamatorios alergicos | |
EA201290570A1 (ru) | Конструкты, связывающиеся с ron, и способы их использования | |
NZ701444A (en) | Antibodies to matrix metalloproteinase 9 | |
CO6710903A2 (es) | Un anticuerpo que reconoce y se une específicamente con un fosfo-epítope en la proteína tau de mamífero o en uno de sus fragmentos y una composición comprendiendo el mismo | |
AR086516A1 (es) | Composiciones anti-peptido relacionado con el gen de la calcitonina y su uso | |
RS52782B (en) | HIGH AFINITY HUMAN ANTIBODIES FOR THE HUMAN IL-4 RECEPTOR | |
EA201370105A1 (ru) | Человеческие антитела против человеческого tnf-подобного лиганда-1а (tl1a) | |
BRPI0821168B8 (pt) | anticorpo isolado que se liga ao il-21 humano, ou um fragmento deste, usos de dito anticorpo ou fragmento, e, hibridoma | |
UA113623C2 (uk) | Моноклональне антитіло проти інгібітору шляху тканинного фактора (tfpi) | |
EA201790757A1 (ru) | Связывающие антиген cd27l белки | |
AR065312A1 (es) | Nuevos anticuerpos | |
EA201491575A1 (ru) | Антитела к матриксной металлопротеиназе 9 | |
JP2016531546A5 (es) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |